Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan.

Dermatol Ther (Heidelb) · 2023 · PMC10149422 · PMID 36905480

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

a significant trendp < 0.001actually significant

There was a significant trend that the longer the duration of drug use, the higher the improvement rate relative to 11% with < 30 days of use ( p < 0.001).

also in 1,253 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.